<SEC-DOCUMENT>0001157523-23-000507.txt : 20230403
<SEC-HEADER>0001157523-23-000507.hdr.sgml : 20230403
<ACCEPTANCE-DATETIME>20230403060205
ACCESSION NUMBER:		0001157523-23-000507
CONFORMED SUBMISSION TYPE:	6-K
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20230403
FILED AS OF DATE:		20230403
DATE AS OF CHANGE:		20230403

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			Innate Pharma SA
		CENTRAL INDEX KEY:			0001598599
		STANDARD INDUSTRIAL CLASSIFICATION:	BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
		IRS NUMBER:				000000000
		STATE OF INCORPORATION:			I0
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		6-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-39084
		FILM NUMBER:		23790268

	BUSINESS ADDRESS:	
		STREET 1:		117 AVENUE DE LUMINY
		STREET 2:		BP 30191
		CITY:			MARSEILLE
		STATE:			I0
		ZIP:			13009
		BUSINESS PHONE:		33430303030

	MAIL ADDRESS:	
		STREET 1:		117 AVENUE DE LUMINY
		STREET 2:		BP 30191
		CITY:			MARSEILLE
		STATE:			I0
		ZIP:			13009

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	Innate Pharma, SA
		DATE OF NAME CHANGE:	20140129
</SEC-HEADER>
<DOCUMENT>
<TYPE>6-K
<SEQUENCE>1
<FILENAME>a53372351.htm
<DESCRIPTION>INNATE PHARMA S.A. 6-K
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using Broadridge PROfile 23.3.1.5138
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div><br>
  </div>
  <div>
    <hr align="center" style="border: none; border-bottom: 1px solid black; border-top: 4px solid black; height: 10px; color: #ffffff; background-color: #ffffff; text-align: center; margin-left: auto; margin-right: auto;"></div>
  <div>
    <div>&#160;</div>
    <div style="text-align: center; margin-right: 6.25pt; margin-left: 6.9pt; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">UNITED STATES</div>
    <div style="text-align: center; margin-right: 6.25pt; margin-left: 6.9pt; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">SECURITIES AND EXCHANGE COMMISSION</div>
    <div style="text-align: center; margin-right: 198.8pt; margin-left: 199.6pt; font-weight: bold;">Washington, D.C. 20549</div>
    <div style="text-align: center; margin-right: 198.8pt; margin-left: 199.6pt; font-weight: bold;"> <br>
    </div>
    <div style="text-align: center; margin-right: 198.8pt; margin-left: 199.6pt; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">FORM 6-K</div>
    <div>&#160;</div>
    <div style="text-align: center; margin-right: 6.75pt; margin-left: 6.9pt; font-weight: bold;">REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16</div>
    <div style="text-align: center; margin-right: 6.75pt; margin-left: 6.9pt; font-weight: bold;">UNDER THE SECURITIES EXCHANGE ACT OF 1934</div>
    <div>&#160;</div>
    <div style="text-align: center; margin-right: 163.55pt; margin-left: 163.6pt; font-weight: bold;">Date of report: For the month of April 2023</div>
    <div style="font-family: 'Times New Roman',Times,serif; font-weight: 400;"> <br>
    </div>
    <div style="text-align: center; margin-right: 163.55pt; margin-left: 163.6pt; font-weight: bold;">Commission File Number: 001-39084</div>
    <div>&#160;</div>
    <div style="text-align: center; margin-right: 6.75pt; margin-left: 6.75pt; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">Innate Pharma S.A.</div>
    <div style="text-align: center; margin-right: 6.75pt; margin-left: 6.75pt;">(Translation of registrant's name into English)</div>
    <div>&#160;</div>
    <div style="text-align: center; margin-right: 6.75pt; margin-left: 6.75pt; font-family: 'Times New Roman',Times,serif; font-size: 12pt; font-weight: bold;">Innate Pharma S.A.</div>
    <div style="text-align: center; margin-right: 6.25pt; margin-left: 6.9pt; font-weight: bold;">117 Avenue de Luminy&#8212;BP 30191</div>
    <div style="text-align: center; margin-right: 6.3pt; margin-left: 6.9pt; font-weight: bold;">13009 Marseille, France</div>
    <div style="text-align: center; margin-right: 6.75pt; margin-left: 2.3pt; font-weight: bold;">+ 33 (0) 4 30 30 30</div>
    <div style="text-align: center; margin-right: 6.3pt; margin-left: 6.9pt;">(Address of principal executive office)</div>
    <div>&#160;</div>
    <div>&#160;</div>
    <div style="font-family: 'Times New Roman',Times,serif;">Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F</div>
    <div style="font-family: 'Times New Roman',Times,serif;">Form 20-F [ X ]&#160;&#160;Form 40-F [ ]</div>
    <div>&#160;</div>
    <div style="font-family: 'Times New Roman',Times,serif;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(1):</div>
    <div style="font-family: 'Times New Roman',Times,serif;"> [&#160; ]</div>
    <div>&#160;</div>
    <div style="font-family: 'Times New Roman',Times,serif;">Indicate by check mark if the registrant is submitting the Form 6-K in paper as permitted by Regulation S-T Rule 101(b)(7):</div>
    <div style="font-family: 'Times New Roman',Times,serif;"> [&#160; ]</div>
    <div><br>
    </div>
    <div>
      <div style="text-align: center; font-weight: bold;">INCORPORATION BY REFERENCE</div>
    </div>
    <div>
      <div><br>
      </div>
      <div>&#160;</div>
      <div>This Report on Form&#160;6-K&#160;[and Exhibit 99.1 to this Report on Form&#160;6-K]&#160;shall be deemed to be incorporated by reference into the registration statement on Form&#160;F-3&#160;(File&#160;No.&#160;333-252074)&#160;of Innate Pharma S.A. (including any prospectuses forming a
        part of such registration statements) and to be a part thereof from the date on which this report is furnished, to the extent not superseded by documents or reports subsequently filed or furnished.</div>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div><br>
    </div>
    <div>&#160;</div>
    <div style="text-align: center; margin-right: 6.25pt; margin-left: 6.9pt; font-weight: bold;">EXHIBIT INDEX</div>
    <div>&#160;</div>
    <div>
      <table cellspacing="0" cellpadding="0" border="0" id="z1089781a2ac441f6b77f0a9d165c8802" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;">

          <tr>
            <td style="width: 8%;"><font style="font-weight: bold;"><u>Exhibit</u></font></td>
            <td style="width: 92%;"><font style="font-weight: bold;"><u>Description</u></font></td>
          </tr>
          <tr>
            <td style="width: 8%;">
              <div>&#160;</div>
            </td>
            <td style="width: 92%;">
              <div>&#160;</div>
            </td>
          </tr>
          <tr>
            <td style="width: 8%;"><a href="a53372351ex99_1.htm">99.1</a><br>
            </td>
            <td style="width: 92%;"><a href="a53372351ex99_1.htm">Press Release dated April 3, 2023</a></td>
          </tr>

      </table>
    </div>
    <div style="margin-left: 5.55pt;"><font style="text-indent: 0px; font-size: 5.11pt;" class="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160; </font><br>
    </div>
    <div>&#160;</div>
    <div class="BRPFPageBreakArea" style="clear: both; margin-top: 10pt; margin-bottom: 10pt;">
      <div class="BRPFPageBreak" style="page-break-after: always;">
        <hr noshade="noshade" style="border-width: 0px; clear: both; margin: 4px 0px; width: 100%; height: 2px; color: #000000; background-color: #000000;"></div>
    </div>
    <div><br>
    </div>
    <div style="text-align: center; margin-right: 6.75pt; margin-left: 6.75pt; font-weight: bold;">SIGNATURES</div>
    <div>&#160;</div>
    <div style="font-family: 'Times New Roman',Times,serif;">Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.</div>
    <div>&#160;</div>
    <div> <br>
    </div>
    <div>
      <div>
        <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; width: 100%; text-align: left; color: #000000;" id="zaa2be150bca0447cb4b15ce8f242ba01">

            <tr>
              <td rowspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
              <td colspan="2" rowspan="1" style="vertical-align: top; font-weight: bold;">INNATE PHARMA S.A.</td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
              <td colspan="2" rowspan="1" style="vertical-align: top;">&#160;</td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 8%; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 42%; vertical-align: top; font-family: 'Times New Roman',Times,serif;">&#160;</td>
            </tr>
            <tr>
              <td style="width: 50%; vertical-align: top; padding-bottom: 2px;">Date: April 3, 2023<font style="text-indent: 0px; font-size: 5.09pt;" class="TRGRRTFtoHTMLTab">&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;&#160;</font></td>
              <td style="width: 8%; vertical-align: top; padding-bottom: 2px;">By:<font style="text-indent: 0px; font-size: 5.2pt;" class="TRGRRTFtoHTMLTab"><br>
                </font></td>
              <td style="width: 42%; vertical-align: top; font-family: 'Times New Roman',Times,serif; border-bottom: 2px solid rgb(0, 0, 0);">/s/ Mondher MAHJOUBI</td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 8%; vertical-align: top;">Name:<br>
              </td>
              <td rowspan="1" style="width: 42%; vertical-align: top; font-family: 'Times New Roman',Times,serif;"> Mondher MAHJOUBI</td>
            </tr>
            <tr>
              <td rowspan="1" style="width: 50%; vertical-align: top;">&#160;</td>
              <td rowspan="1" style="width: 8%; vertical-align: top;">Title:<br>
              </td>
              <td rowspan="1" style="width: 42%; vertical-align: top; font-family: 'Times New Roman',Times,serif;"><font style="font-family: 'Times New Roman', Times, serif;">Chairman of the Executive Board and Chief Executive Officer</font></td>
            </tr>

        </table>
      </div>
    </div>
    <div><br>
    </div>
    <div><br>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>a53372351ex99_1.htm
<DESCRIPTION>EXHIBIT 99.1
<TEXT>
<html>
  <head>
    <title></title>
    <!-- Licensed to: Business Wire
         Document created using Broadridge PROfile 23.3.1.5138
         Copyright 1995 - 2023 Broadridge -->
  </head>
<body bgcolor="#ffffff" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; text-align: left; color: #000000;">
  <div>
    <table cellspacing="0" cellpadding="0" border="0" style="font-family: 'Times New Roman', Times, serif; font-size: 10pt; color: #000000; width: 100%;" id="zf6e5981f906c480c9b3877e233525744">

        <tr>
          <td style="width: 100%; text-align: right;"><font style="font-weight: bold;">Exhibit 99.1</font><br>
          </td>
        </tr>

    </table>
    <div> <br>
    </div>
    <div>
      <div class="bw-release">
        <h1 style="text-align: center; list-style-position: inside;FONT-SIZE: 14pt;"> <b>Innate Pharma Announces Exclusive License of Antibodies to Takeda for Celiac Disease Research Program</b> </h1>
        <div class="bw-release-subhead">
          <ul style="list-style-type: disc;">
            <b>
              <li> <b><i>Takeda to obtain exclusive worldwide rights to develop, manufacture and commercialize Antibody Drug Conjugates (ADC) using a panel of selected antibodies developed by Innate</i></b> </li>
            </b>
          </ul>
        </div>
        <div class="bw-release-body">
          <div class="bw-release-table-js bw-release-story">
            <p>MARSEILLE, France--(BUSINESS WIRE)--April 3, 2023--Innate Pharma SA (Euronext Paris: IPH; Nasdaq: IPHA) today announced that it has entered into an exclusive license agreement with Takeda under which Innate grants Takeda exclusive worldwide
              rights to research and develop antibody drug conjugates (ADC) using a panel of selected Innate antibodies against an undisclosed target, with a primary focus in Celiac disease. </p>
            <p> Takeda will be responsible for the future development, manufacture and commercialization of any potential products developed using the licensed antibodies. </p>
            <p> <b>Yannis Morel, Ph.D., Executive Vice President, Product portfolio strategy &amp; Business development at Innate Pharma</b> </p>
            <p> <i>&#8220;We are thrilled to be working with Takeda, a company which has been very successful in developing new drugs across multiple therapeutic areas. This agreement expands the application of Innate&#8217;s science beyond our oncology focus and
                demonstrates how our antibody engineering expertise can play a major role in developing Antibody Drug Conjugate formats. Our antibody platform has the broad ability to contribute to modalities not only via NK Cell Engagers through our ANKET<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>
                technology but also with Antibody Drug Conjugates.&#8221;</i> </p>
            <p> Under the terms of the license agreement, Innate will receive a $5m upfront payment and is eligible to receive up to $410m in future development, regulatory and commercial milestones if all milestones are achieved during the term of the
              agreement, plus royalties on potential net sales of any commercial product resulting from the license. </p>
            <p> <b>About Innate Pharma</b> </p>
            <p> Innate Pharma S.A. is a global, clinical-stage biotechnology company developing immunotherapies for cancer patients. Its innovative approach aims to harness the innate immune system through therapeutic antibodies and its ANKET<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup> (<b>A</b>ntibody-based
              <b>NK</b> cell <b>E</b>ngager <b>T</b>herapeutics) proprietary platform. </p>
            <p> Innate&#8217;s portfolio includes lead proprietary program lacutamab, developed in advanced form of cutaneous T cell lymphomas and peripheral T cell lymphomas, monalizumab developed with AstraZeneca in non-small cell lung cancer, as well as ANKET<sup style="vertical-align: text-top; line-height: 1; font-size: smaller;">&#174;</sup>
              multi-specific NK cell engagers to address multiple tumor types. </p>
            <p> Innate Pharma is a trusted partner to biopharmaceutical companies such as Sanofi and AstraZeneca, as well as leading research institutions, to accelerate innovation, research and development for the benefit of patients. </p>
            <p> Headquartered in Marseille, France with a US office in Rockville, MD, Innate Pharma is listed on Euronext Paris and Nasdaq in the US. </p>
            <div> </div>
            <div style="MARGIN-BOTTOM: 10pt; CLEAR: both; MARGIN-TOP: 10pt" id="DSPFPageBreakArea">
              <div style="PAGE-BREAK-AFTER: always" id="DSPFPageBreak">
                <hr style="BORDER-LEFT-WIDTH: 0px; HEIGHT: 2px; BORDER-RIGHT-WIDTH: 0px; WIDTH: 100%; BORDER-BOTTOM-WIDTH: 0px; COLOR: #000000; CLEAR: both; MARGIN: 4px 0px; BORDER-TOP-WIDTH: 0px; BACKGROUND-COLOR: #000000"> </div>
            </div>
            <p> Learn more about Innate Pharma at www.innate-pharma.com and follow us on Twitter and LinkedIn. </p>
            <p> <b>Information about Innate Pharma shares</b> </p>
            <table cellspacing="0" id="z1f78b8bca257418eb5d93c7c6eca3b64" style="margin-bottom: 10px;margin-left: 0px; margin-right: auto; font-size: 10pt;">

                <tr>
                  <td colspan="1" rowspan="1" style="vertical-align: top;padding-left: 0px;">
                    <p style="text-align: left;margin-bottom: 0px; margin-top: 0px;"> <b>ISIN code</b> </p>
                  </td>
                  <td colspan="1" rowspan="1">&#160;</td>
                  <td colspan="1" rowspan="1" style="vertical-align: top;padding-left: 0px;">
                    <p style="margin-bottom: 0px; margin-top: 0px;"> FR0010331421 </p>
                  </td>
                </tr>
                <tr>
                  <td colspan="1" rowspan="1" style="vertical-align: top;padding-left: 0px;">
                    <p style="text-align: left;margin-bottom: 0px; margin-top: 0px;"> <b>Ticker code</b> </p>
                  </td>
                  <td colspan="1" rowspan="1">&#160;</td>
                  <td colspan="1" rowspan="1" style="vertical-align: top;padding-left: 0px;">
                    <p style="margin-bottom: 0px; margin-top: 0px;"> Euronext: IPH Nasdaq: IPHA </p>
                  </td>
                </tr>
                <tr>
                  <td colspan="1" rowspan="1" style="vertical-align: top;padding-left: 0px;">
                    <p style="text-align: left;margin-bottom: 0px; margin-top: 0px;"> <b>LEI</b> </p>
                  </td>
                  <td colspan="1" rowspan="1">&#160;</td>
                  <td colspan="1" rowspan="1" style="vertical-align: top;padding-left: 0px;">
                    <p style="margin-bottom: 0px; margin-top: 0px;"> 9695002Y8420ZB8HJE29 </p>
                  </td>
                </tr>

            </table>
            <p> <b>Disclaimer on forward-looking information and risk factors</b> </p>
            <p> This press release contains certain forward-looking statements, including those within the meaning of the Private Securities Litigation Reform Act of 1995. The use of certain words, including &#8220;believe,&#8221; &#8220;potential,&#8221; &#8220;expect&#8221; and &#8220;will&#8221; and
              similar expressions, is intended to identify forward-looking statements. Although the company believes its expectations are based on reasonable assumptions, these forward-looking statements are subject to numerous risks and uncertainties,
              which could cause actual results to differ materially from those anticipated. These risks and uncertainties include, among other things, the uncertainties inherent in research and development, including related to safety, progression of and
              results from its ongoing and planned clinical trials and preclinical studies, review and approvals by regulatory authorities of its product candidates, the Company&#8217;s commercialization efforts and the Company&#8217;s continued ability to raise
              capital to fund its development. For an additional discussion of risks and uncertainties which could cause the company's actual results, financial condition, performance or achievements to differ from those contained in the forward-looking
              statements, please refer to the Risk Factors (&#8220;Facteurs de Risque") section of the Universal Registration Document filed with the French Financial Markets Authority (&#8220;AMF&#8221;), which is available on the AMF website http://www.amf-france.org or
              on Innate Pharma&#8217;s website, and public filings and reports filed with the U.S. Securities and Exchange Commission (&#8220;SEC&#8221;), including the Company&#8217;s Annual Report on Form 20-F for the year ended December 31, 2021, and subsequent filings and
              reports filed with the AMF or SEC, or otherwise made public, by the Company. </p>
            <p> This press release and the information contained herein do not constitute an offer to sell or a solicitation of an offer to buy or subscribe to shares in Innate Pharma in any country. </p>
          </div>
          <div class="bw-release-contact">
            <h2 style="FONT-SIZE: 14pt;">Contacts</h2>
            <p> <b>For additional information, please contact: </b><br>
              <b><u>Investors </u></b><br>
              <b>Innate Pharma </b><br>
              Henry Wheeler <br>
              Tel.: +33 (0)4 84 90 32 88 <br>
              Henry.wheeler@innate-pharma.fr </p>
            <p> <b><u>Media Relations </u></b><br>
              <b>NewCap </b><br>
              Arthur Rouill&#233; <br>
              Tel.: +33 (0)1 44 71 00 15 <br>
              innate@newcap.eu </p>
          </div>
        </div>
      </div>
    </div>
  </div>
</body>
</html>
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
